Abstracts tagged "gout"

Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 1581 • ACR Convergence 2022
Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study
Nalia Domínguez-Lirón¹, Eugenio De Miguel², Agustín Martínez-Sanchis³, Diana Peiteado², Blanca Garcia-Magallon⁴, Esther Vicente-Rabaneda⁵, Enrique Calvo⁶, Basilio Rodríguez⁷, Alejandro Prada⁸, Boris Anthony Blanco Cáceres⁹, José Antonio Bernal¹⁰, Francisca Sivera¹¹, Santos Castañeda⁵, Sonia Mínguez⁷, Laura Barrio⁸, Mónica Vázquez-Díaz⁹, José Miguel Senabre¹², Cristina Bohorquez¹³ and Mariano Andrès³, ¹Miguel Hernández University, Alicante, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Althaia Xarxa Assistencial Universitaria De Manresa, Manresa, Spain, ⁸Hospital Universitario de Torrejon, Madrid, Spain, ⁹Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁰Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ¹¹Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹²Hospital Marina Baixa, Villajoyosa, Spain, ¹³University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain
Background/Purpose: The applicability of the preliminary remission criteria for gout [PMID 26414176] in clinical practice is unknown. This study evaluates the sonographic prevalence of monosodium…
Abstract Number: 1798 • ACR Convergence 2022
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in gout management, centered on the titration of urate lowering therapy (ULT) to a goal serum urate (SU)…
Abstract Number: 1816 • ACR Convergence 2022
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
Ira Khanna, Venkatesh Mani, Renata Pyzik, Audrey Kaufman, Wei Wei Chi, Emilia Bagiella, Philip Robson and Yousaf Ali, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Gout is the most common inflammatory arthritis, caused by hyperuricemia and subsequent deposition of aggregated monosodium urate (MSU) crystals in both articular and extra-articular…
Abstract Number: 1582 • ACR Convergence 2022
Allopurinol Use and Risk of Acute Coronary Syndrome in Patients with Incident Gout: A Population-based Study in Sweden
Panagiota Drivelegka¹, Lennart Jacobsson², Karin Bengtsson³ and Mats Dehlin⁴, ¹Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ³Department of Rheumatology and Inflammation research, University of Gothenburg, Salhgrenska Academy, Gothenburg, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Gout is associated with an increased risk of cardiovascular disease, with accumulated evidence that gout is an independent risk factor. Whether allopurinol use alters…
Abstract Number: 1799 • ACR Convergence 2022
Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
Naomi Schlesinger¹, Michael Pillinger² and Peter Lipsky³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²NYU Grossman School of Medicine, New York, NY, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: The American College of Rheumatology (ACR) developed an updated guideline in 2020 for the management of gout.1 This study evaluates US rheumatologists' stated adherence…
Abstract Number: 1818 • ACR Convergence 2022
Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
Naomi Schlesinger¹, ankoor patel¹, Vinod Rustgi¹, Anthony Yeo² and Peter Lipsky³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizontherapeutics, New York, NY, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD), but neither the frequency nor severity of NAFLD in gout is well described. Elastography is…
Abstract Number: 0001 • ACR Convergence 2022
12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
John Botson¹, kenneth saag², Jeff Peterson³, Katie Obermeyer⁴, Brian LaMoreaux⁴, Suneet Grewal⁵, Amar Majjhoo⁶, John Tesser⁷ and Michael Weinblatt⁸, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²University of Alabama at Birmingham, Birmingham, AL, ³Western Washington Arthritis Clinic, Seattle, WA, ⁴Horizon Therapeutics plc, Deerfield, IL, ⁵East Bay Rheumatology Medical Group, Inc., San Leandro, CA, ⁶Shores Rheumatology, PC, Troy, MI, ⁷Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The MIRROR RCT trial examined pegloticase (PEGylated uricase) safety and efficacy with methotrexate (MTX) vs placebo (PBO) as co-therapy. Sustained urate-lowering rate during Month…
Abstract Number: 1583 • ACR Convergence 2022
Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in the management of gout, involving titration of urate lowering therapy (ULT) to a serum urate (SU) goal…
Abstract Number: 1800 • ACR Convergence 2022
Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
Yue Yin¹, Yun Zhang¹, Hong Di¹, Xinxin Han¹ and Xuejun Zeng², ¹Peking Union Medical College Hospital, Beijing, China, ²Department of General Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: Gout is an inflammatory disease caused by the deposition of MSU crystals in joints and other parts. At present, little progress in the research…
Abstract Number: 1820 • ACR Convergence 2022
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Blanka Stiburkova¹, Kateřina Pavelcová¹, Jana Bohatá¹, Karel Pavelka², Lenka Hasíková¹, Jakub Závada¹, Aleš Kvasnička³, Dana Dobešová³ and David Friedecký³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ³Palacky University Olomouc, Olomouc, Czech Republic
Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…
Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Robert Terkeltaub¹, JuneSik Mune², Jieun Lee³ and Kenneth Saag⁴, ¹VA/UCSD, San Diego, CA, ²LG Chem, Ltd., Seoul, ³LG Chem, Ltd., Seoul, South Korea, ⁴The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…
Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
Abstract Number: 0661 • ACR Convergence 2021
Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Lisa Stamp¹, Rebecca Grainger², Chris Frampton¹, Jill Drake¹ and Catherine Hill³, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Wellington, New Zealand, ³Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), also known as omega-3 fats act as alternate COX substrates to arachidonic acid (AA). Their metabolism results…
Abstract Number: 0678 • ACR Convergence 2021
Is There a Difference in Self-reported Flare Frequency Between Men and Women?
Naomi Schlesinger¹, Nicholas A Sumpter², Nicola Dalbeth³, Lisa Stamp⁴ and Tony Merriman⁵, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: There is increasing recognition of gout among women. The postmenopausal rise in serum urate levels in women increases the risk for the development of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].